2017
Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival
Moore LM, England A, Ehrlich BE, Rimm DL. Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival. Molecular Cancer Research 2017, 15: 942-952. PMID: 28275088, PMCID: PMC5500411, DOI: 10.1158/1541-7786.mcr-16-0408.Peer-Reviewed Original ResearchConceptsBreast cancer cellsNCS-1Breast cancer patient cohortsNCS-1 expressionLymph node statusCancer cellsShorter survival rateIndependent breast cancer cohortsCancer patient cohortsBreast cancer cohortMB-231 breast cancer cellsPaclitaxel-induced cell deathAggressive tumor phenotypeNeuronal model systemClinical outcomesClinicopathologic featuresNeuronal calcium sensor-1Node statusPatient cohortProgesterone receptorWorse outcomesBreast cancerCalcium-binding proteinsCancer cohortEstrogen receptor
2012
Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues
Neumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER, Vassilakopoulou M, Parisi F, Kluger Y, Hicks DG, Rimm DL. Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues. Journal Of The National Cancer Institute 2012, 104: 1815-1824. PMID: 23090068, PMCID: PMC3514166, DOI: 10.1093/jnci/djs438.Peer-Reviewed Original ResearchMeSH KeywordsA Kinase Anchor ProteinsBiomarkers, TumorBiopsy, Large-Core NeedleBreast NeoplasmsCold IschemiaConfounding Factors, EpidemiologicFalse Negative ReactionsFemaleFixativesFluorescent Antibody TechniqueFormaldehydeGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitKi-67 AntigenMastectomy, SegmentalMatched-Pair AnalysisMinor Histocompatibility AntigensProspective StudiesProto-Oncogene ProteinsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneResearch DesignTime FactorsConceptsCold ischemic timeIschemic timeBreast cancer tissuesEstrogen receptorCancer tissuesLoss of antigenicityBreast cancer resectionProtein expressionCore needle biopsyCompanion diagnostic testsConditions of hypoxiaFalse-negative resultsBreast cancer biomarkersCancer resectionProgesterone receptorNeedle biopsyRecent guidelinesCold ischemiaBreast cancerTissue microarrayEvidence of lossQuantitative immunofluorescenceDiagnostic testsAntigenicityAQUA methodStathmin expression and its relationship to microtubule‐associated protein tau and outcome in breast cancer
Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, Rimm DL. Stathmin expression and its relationship to microtubule‐associated protein tau and outcome in breast cancer. Cancer 2012, 118: 4660-4669. PMID: 22359235, PMCID: PMC3391341, DOI: 10.1002/cncr.27453.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnalysis of VarianceBiomarkers, TumorBlotting, WesternBreastBreast NeoplasmsCell Line, TumorCohort StudiesFemaleFluorescent Antibody TechniqueGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPredictive Value of TestsPrognosisProportional Hazards ModelsRisk AssessmentRisk FactorsRNA, Small InterferingStathminTau ProteinsTissue Array AnalysisTreatment OutcomeConceptsHigh stathmin expressionDisease-free survivalMAP-tauOverall survivalStathmin expressionBreast cancerHuman epidermal growth factor receptor 2 (HER2) expressionEpidermal growth factor receptor 2 expressionMultivariate analysisCox proportional hazards modelWorse overall survivalReceptor 2 expressionTissue microarray formatMicrotubule-associated protein tauProportional hazards modelBreast cancer cohortIndependent predictorsMenopausal statusNodal statusBetter prognosisPrognostic valueTumor sizePathological characteristicsProgesterone receptorNuclear grade
2010
Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry
Siddiqui S, Rimm DL. Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry. Breast Cancer Research 2010, 12: 113. PMID: 21176180, PMCID: PMC3046444, DOI: 10.1186/bcr2782.Peer-Reviewed Original ResearchConceptsCold ischemic timePre-analytic variablesIschemic timeCore needle biopsyCompanion diagnostic testingCompanion diagnostic testsBreast cancer researchProgesterone receptorNeedle biopsyBreast cancerEstrogen receptorCritical therapyDiagnostic testingDiagnostic testsClassic markersImmunohistochemistryCancer researchPhospho-specific antibodiesReceptorsMarkersAchilles heelThe ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium
Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA, Jones FE. The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Molecular Cancer 2010, 9: 150. PMID: 20550710, PMCID: PMC2894764, DOI: 10.1186/1476-4598-9-150.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsCell Line, TumorErbB ReceptorsEstrogen Receptor alphaFemaleGene ExpressionGene Expression RegulationHumansMammary Glands, AnimalMammary Glands, HumanMiceMice, TransgenicPregnancyReceptor, ErbB-4Receptors, ProgesteroneReverse Transcriptase Polymerase Chain ReactionSignal TransductionConceptsPgR expressionExpression of PgRBreast cancerERα coactivatorMammary glandHER4 intracellular domainProgesterone receptor expressionPositive breast carcinomaMalignant breast epitheliumPrimary breast tumorsMCF-7 variantEstrogen receptor coactivatorBreast tumor cell linesCell linesBreast tumor cellsTamoxifen responseMouse mammary glandProgesterone receptorReceptor expressionBreast carcinomaMCF-7 breast tumor cell linePatient responseBreast carcinogenesisEstrogen stimulationBreast epitheliumMultiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows that Both High and Low Levels of HER2 Are Associated with Poor Outcome. American Journal Of Pathology 2010, 176: 1639-1647. PMID: 20150438, PMCID: PMC2843456, DOI: 10.2353/ajpath.2010.090711.Peer-Reviewed Original ResearchConceptsDisease-free survivalEstrogen receptorContinuous variablesSouthwest Oncology GroupAQUA methodAC chemotherapyMenopausal statusNegative patientsOncology GroupNode statusSequential doxorubicinPoor outcomeTumor sizeProgesterone receptorPrognostic informationWorse outcomesTissue biomarkersTissue microarrayBiphasic effectP53 expressionPatientsHER2Low expressersDiagnostic approachMultiplexed assessment
2009
DNA Hypermethylation of ESR1 and PGR in Breast Cancer: Pathologic and Epidemiologic Associations
Gaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, Peplonska B, Brinton LA, Rimm DL, Laird PW, Garcia-Closas M, Sherman ME. DNA Hypermethylation of ESR1 and PGR in Breast Cancer: Pathologic and Epidemiologic Associations. Cancer Epidemiology Biomarkers & Prevention 2009, 18: 3036-3043. PMID: 19861523, PMCID: PMC2783691, DOI: 10.1158/1055-9965.epi-09-0678.Peer-Reviewed Original ResearchConceptsBreast cancerPopulation-based case-control studyBreast cancer risk factorsPromoter CLevels of ERalphaPR-negative tumorsInvasive breast cancerCancer risk factorsCase-control studyPercentage of tumorsNegative breast cancerTumor tissue coresImproved risk predictionLower ERalphaTumor characteristicsPR expressionProgesterone receptorEpidemiologic associationRisk factorsInverse associationDNA hypermethylationPR levelsMost tumorsReceptor silencingTumors
2008
Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Research 2008, 10: r35. PMID: 18430249, PMCID: PMC2397537, DOI: 10.1186/bcr1998.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDNA-Binding ProteinsDrug Resistance, NeoplasmFemaleFluorescent Antibody TechniqueFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMiddle AgedPredictive Value of TestsPrognosisProportional Hazards ModelsProtein Array AnalysisProto-Oncogene Proteins c-bcl-2Receptors, EstrogenReceptors, ProgesteroneTranscription FactorsTreatment OutcomeConceptsNode-positive subsetHER2/neuProgesterone receptorBreast cancerEstrogen receptorBcl-2 expressionBAG-1 expressionImproved survivalBcl-2Anti-apoptotic mediator Bcl-2Breast tumorsSteroid receptor positivitySubset of patientsBAG-1Antihormonal therapyFavorable prognosisReceptor positivityMultivariable analysisPathological variablesEntire cohortPrognostic valuePrognostic markerImproved outcomesLarge cohortClinical development
2007
Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study
Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dąbrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, García-Closas M. Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 439-443. PMID: 17372238, DOI: 10.1158/1055-9965.epi-06-0806.Peer-Reviewed Original ResearchConceptsBasal-like tumorsMolecular subtypesBreast cancerClinical featuresRisk factorsRelative riskBreast cancer risk factorsBreast cancer molecular subtypesHuman epidermal growth factor receptorUnfavorable clinical featuresInvasive breast cancerBody mass indexCancer risk factorsDistinct clinical featuresCancer molecular subtypesEstrogen receptor alphaEpidermal growth factor receptorBreast Cancer StudyPolish Breast Cancer StudyGrowth factor receptorPremenopausal womenMass indexPathologic featuresProgesterone receptorOdds ratioQuantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome
Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007, 25: 19-26. PMID: 17364553, DOI: 10.1080/07357900601128825.Peer-Reviewed Original ResearchConceptsCOX-2 expressionCOX-2Tissue microarrayBreast cancerEstrogen receptorPrognostic factorsWorse survivalProgesterone receptorX-tileOptimal cutpointHigh COX-2 expressionBreast cancer tissue microarrayX-tile analysisSignificant prognostic factorsPrimary breast cancerCOX-2 inhibitorsCancer tissue microarrayHER2/neuClinicopathologic factorsNodal statusPoor outcomePoor prognosisTumor sizePredictive biomarkersClinical trials
2006
Construction and Validation of Tissue Microarrays of Ductal Carcinoma In Situ and Terminal Duct Lobular Units Associated With Invasive Breast Carcinoma
Yang XR, Charette LA, Garcia-Closas M, Lissowska J, Paal E, Sidawy M, Hewitt SM, Rimm DL, Sherman ME. Construction and Validation of Tissue Microarrays of Ductal Carcinoma In Situ and Terminal Duct Lobular Units Associated With Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2006, 15: 157-161. PMID: 16932071, DOI: 10.1097/01.pdm.0000213453.45398.e0.Peer-Reviewed Original ResearchConceptsTerminal duct lobular unitsTissue microarrayEstrogen receptorDuctal carcinomaProgesterone receptorBreast cancerLobular unitsLarge case-control studyPR expression levelsCase-control studyInvasive breast carcinomaPercentage of tubulesInvasive carcinomaEpithelial lesionsBreast carcinomaImmunohistochemical characterizationImmunohistochemical stainingPeritumoral tissuesPositive stainingScoring systemCarcinomaCategorical scoring systemBreast tissueMethodologic studyExpression levelsQuantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome
Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome. Cancer Research 2006, 66: 5487-5494. PMID: 16707478, DOI: 10.1158/0008-5472.can-06-0100.Peer-Reviewed Original ResearchConceptsProgesterone receptorEstrogen receptorPrognostic valueBreast cancerKi-67X-tile softwareProportional hazards modelBreast cancer prognosisBreast cancer showBreast cancer tumorsΒ-catenin expressionYale Pathology archivesHazard ratioNode statusPoor outcomeTumor sizePrognostic markerWorse outcomesImmunohistochemical studyNuclear gradeCase cohortLow-level expressionPathology archivesTissue microarrayBeta-catenin expression
2005
Immunohistochemical Biomarkers in Patients with Early-Onset Breast Carcinoma by Tissue Microarray
Choi DH, Kim S, Rimm DL, Carter D, Haffty BG. Immunohistochemical Biomarkers in Patients with Early-Onset Breast Carcinoma by Tissue Microarray. The Cancer Journal 2005, 11: 404-411. PMID: 16259871, DOI: 10.1097/00130404-200509000-00008.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAdultBiomarkers, TumorBreast NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunohistochemistryKi-67 AntigenMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasms, Ductal, Lobular, and MedullaryProtein Array AnalysisProto-Oncogene Proteins c-bcl-2Receptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTime FactorsTumor Suppressor Protein p53Women's HealthConceptsHER-2/neuBreast cancerProgesterone receptorKi-67Local relapseNodal statusYoung womenDistant metastasisTumor stageBiologic markersEstrogen receptorRelapse-free survival rateDistant metastasis-free rateDistant relapse-free survival ratesEarly-stage breast cancerEarly-onset breast cancerEarly-onset breast carcinomaProgesterone receptor negativityGroup of patientsMetastasis-free rateBcl-2Ki-67 positivityParaffin-embedded specimensTissue microarray methodConservative surgery
2004
Molecular markers for prognosis after isolated postmastectomy chest wall recurrence
Haffty BG, Hauser A, Choi DH, Parisot N, Rimm D, King B, Carter D. Molecular markers for prognosis after isolated postmastectomy chest wall recurrence. Cancer 2004, 100: 252-263. PMID: 14716758, DOI: 10.1002/cncr.11915.Peer-Reviewed Original ResearchConceptsHER-2/neu statusChest wall recurrencePositive HER-2/neu statusLocal-regional controlLocal recurrenceNeu statusDistant metastasisPR statusProgesterone receptorBreast carcinomaDistant metastasis-free survival ratesLocal chest wall recurrenceDistant metastasis-free rateMetastasis-free survival ratesHER-2/neuLymph node recurrencePositive PR statusProgression-free rateSimultaneous distant metastasesOperable breast carcinomaLocal-regional recurrenceMetastasis-free ratePostmastectomy chest wallExternal beam radiotherapyLong-term survival
2003
BRCA Status, Molecular Markers, and Clinical Variables in Early, Conservatively Managed Breast Cancer
Kim S, Rimm D, Carter D, Khan A, Parisot N, Franco MA, Bale A, Haffty BG. BRCA Status, Molecular Markers, and Clinical Variables in Early, Conservatively Managed Breast Cancer. The Breast Journal 2003, 9: 167-174. PMID: 12752624, DOI: 10.1046/j.1524-4741.2003.09307.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCohort StudiesFemaleGenetic Predisposition to DiseaseHumansImmunohistochemistryMutationNeoplasm Recurrence, LocalPremenopauseProliferating Cell Nuclear AntigenReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTumor Suppressor Protein p53ConceptsHER-2/neuEstrogen receptorProgesterone receptorBRCA-1BRCA-2Breast cancerBRCA mutationsProliferating Cell Nuclear AntigenMolecular biologic markersPremenopausal breast cancerBRCA-1 mutationsBreast-conserving surgeryWide local excisionBreast cancer patientsPrimary breast tumor tissuesAvailable paraffin blocksBRCA-2 genesBreast tumor tissuesFamilial breast cancerCell nuclear antigenAxillary dissectionPR negativityPremenopausal womenLocal relapseSystemic therapy
2000
Validation of Tissue Microarray Technology in Breast Carcinoma
Camp R, Charette L, Rimm D. Validation of Tissue Microarray Technology in Breast Carcinoma. Laboratory Investigation 2000, 80: 1943-1949. PMID: 11140706, DOI: 10.1038/labinvest.3780204.Peer-Reviewed Original ResearchConceptsWhole tissue sectionsInvasive breast carcinomaBreast carcinomaTissue microarray technologyLarge-scale retrospective cohort studyTissue sectionsArchival tissueRetrospective cohort studyHER2/neu oncogeneTissue microarray techniqueCohort studyBreast cancer microarrayProgesterone receptorArchival cohortEstrogen receptorAmount of tissueCommon antigenNeu oncogeneEntire tumorCarcinomaProtein expressionProtein expression patternsArchival formalinTissueReceptors